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Complement receptor type 1 (CR1)/the C3b/C4b receptor (1), and CR3, the 
iC3b receptor (2),  of myelomonocytic cells have been shown to be involved in 
the phagocytosis of particles bearing the C3b and iC3b cleavage fragments of 
C3. Two states of activity exist for these receptors, a resting state, in which CR1 
and CR3 only bind ligand-coated particles, and an activated state, in which these 
receptors also mediate the phagocytosis of such particles. The activated state was 
first described  (3)  when  complement receptors on  murine peritoneal  macro- 
phages were shown to acquire phagocytic capability after treatment of cells with 
soluble products of activated T  cells. Subsequently, PMA was bound to impart 
phagocytic function on CR1  and CR3 of human monocytes and neutrophils (4, 
5), and also to induce ligand-independent internalization of CRI  by these cells 
(6). Finally, the capacity of three proteins of the extracellular matrix, fibronectin 
(FN) (5, 7, 8), serum amyloid P (5), and laminin (9), and activate CR1  and CR3 
suggests that this alteration of receptor function may occur physiologically when 
cells migrate to the extravascular space. 
The biochemical reactions accounting for the transition of CR 1 and CR3 from 
the resting to the activated state are not known, but the ability of PMA to induce 
this  transition  suggests that protein phosphorylation by protein kinase C  (I0) 
may be an important event. Therefore, we have assessed the phosphorylation of 
these proteins by phagocytic and nonphagocytic cells. CR1  of myelomonocytic 
cells became pbosphorylated following treatment of cells with PMA. In contrast, 
PMA  did  not  induce  phosphorylation  of CR1  in  tonsilar  cells  containing  B 
lymphocytes, B lymphoblastoid cells, or erythrocytes, although relatively intense 
phosphorylation of CR2 (11), the C3d/EBV receptor (12), was observed in both 
tonsilar B cells and B lymphoblastoid cells. 
Materials and Methods 
Chemicals.  BSA (fatty acid-free, fraction V; Miles Laboratories,  Kankakee, IL), SDS 
(BioRad Laboratories,  Richmond, CA), NP-40 (BDH Chemicals, Ltd.,  Poole, England), 
This work  was supported  by  grants  AI-22531,  A1-10356,  AI-22833,  A1-19397,  RR-05669,  RR- 
01996,  AM-36308,  and  AM-35907  from  the  National  Institutes  of  Health,  Bethesda,  MD.  P. 
Changelian  is  a  predoctoral  trainee of the  National  Cancer  Institute  (grant  5-T32-CA-090141). 
Address correspondence to Douglas T. Fearon, Seeley G. Mudd Building, Rm. 607,250 Longwood 
Avenue, Boston, MA 02115. 
1Abbreviations  used in  this paper:  CRI,  C3b/C4b  receptor;  CR2,  C3d  receptor;  CR3,  iC3b 
receptor; FN, fibronectin. 
J. ExP.  MEt). © The Rockefeller University Press • 0022-1007/86/1/0101/15  $1.00  101 
Volume 163  January 1986  101-115 102  COMPLEMENT  RECEPTOR  PHOSPHORYLAT1ON 
CNBr-activated Sepharose  4  B  and  protein  A-Sepharose  (Pharmacia  Fine  Chemicals, 
Piscataway, N  J) were purchased. All other chemicals were purchased from Sigma Chemical 
Co., St.  Louis, MO. 
Antibodies.  YZ-1  isan lgG1 monoclonalanti-CR1 (6). 3GS.10monoclonalanti-human 
neutrophil  FcR  (13)  was a  gift of Dr. Jay  Unkeless,  The  Rockefeller University,  New 
York. HB-5 is an IgG2a monoclonal anti-CR2 (11).  W6/32, an IgG2a mAb, recognizes a 
common determinant on the HLA-A, -B, and -C heavy cbain (14).  MMA, a monoclonal 
IgM that recognizes a determinant on myelomonocytic cells (15), was a gift of Dr. Thomas 
Tedder, Dana-Farber Cancer Institute, Boston, MA. B1, an IgG2a mAb that recognizes 
a determinant on human B lymphocytes (16) (Coulter Immunology, Hialeab, FL); OKM 1, 
an IgG2b mAb directed at human CR3 (2); OKT3, an mAb specific for human T  cells 
(17) (Ortho Pharmaceuticals,  Raritan,  NJ);  UPC10,  an  IgG2a myeloma with specificity 
for levan; MOPC 141, an IgG2b myeloma with no known specificity (Bionetics, Kensing- 
ton, MD); and FITC-labeled goat F(ab')~ anti-mouse F(ab')~ (Jackson ImmunoResearcb 
Labs, Inc., Avondale, PA), were purchased. Antibodies were coupled to CNBr-activated 
Sepharose 4 B at a ratio of 1-2 mg protein per milliliter gel. 
Flow cytometric analysis for membrane protein expression was performed using the 
Ortho Systems 50  H  Cytofluorograf (Ortho  Diagnostics, Westwood,  MA) as described 
(6). 
Cell Preparations.  Human  erythrocytes were obtained from citrated blood after re- 
peated washings and removal of buffy-coat cells.  Neutrophils were purified from periph- 
eral blood by dextran sedimentation and centrifugation through Ficoll-Paque (18). Tonsils 
were obtained after routine  tonsillectomy.  Single-cell  suspensions  were  prepared,  and 
contaminating  neutrophils  and  erythrocytes were  removed  by centrifugation  through 
Ficoll-Paque. Adherent cells were depleted during a  1-h incubation at 37 °C of tonsil cells 
in plastic tissue culture plates (Costar, Cambridge, MA).  Contaminating macrophages in 
the final lymphocyte preparation were counted by fluorescent flow cytography of MMA- 
stained cells.  Peripheral blood monocytes were purified (19) by elutriation using a J2-21 
centrifuge (Beckman Instruments, Inc., Palo Alto, CA) equipped with a JE-6 elutriator 
rotor with one standard separation chamber. The purity of the monocytes was >85%, as 
assessed by MMA-staining.  Eosinophils were purified to >98% purity on discontinuous 
gradients of hypertonic Metrizamide (20). Cells of the human B lymphoblastoid line SB 
(21) were maintained in RPMI-1640 medium with 10% FBS. 
Preparation of ~2PO4-labeled Cells.  Cells  were labeled with 3~p by a modification of a 
previously described procedure (22).  107 cells/ml were initially depleted of intracellular 
phosphate by incubation  with  buffer lacking PO4  -3  (30  mM  Hepes,  pH  7.4,  110  mM 
NaCI, I 0 mM KCI, I 0 mM glucose,  1 mM CaCI2,  1 mM MgCI2, 2 mM L-glutamine, and 
2 mg/ml BSA) for 60 rain at 37°C. Cells were resuspended to 5 X 107 cells/ml in buffer 
with  "~'~P-labeled  phosphoric acid  (orthophosphoric acid,  50 mCi/ml in  HCl-free water; 
New England Nuclear, Boston, MA) at 1 mCi/ml for 90 rain at 37°C. After labeling, cells 
were  washed  twice,  resuspended  in  buffer,  and  immediately subjected  to appropriate 
stimulation. 
Immunoprecipitation  and  SDS-PAGE Analysis  of Membrane  Proteins.  Phosphorylation 
reactions were stopped and ceils were lysed by the addition of an equal volume of ice-cold 
2x  RIPA  buffer  (2%  NP-40,  0.2%  SDS,  0.15  M  NaCl,  10  mM  NaH~PO4,  10  mM 
Na.~HPO4, 0.68 M sucrose, 5 mM EDTA,  10 mM NaF, 5 mM sodium pyrophosphate, 1 
mM sodium vanadate,  1 mM ATP,  10 mM DFP,  2 ~M leupeptin, 2 #M peptstatin,  100 
/~g/ml  DNase,  5%  FCS,  pH  7.2).  This  lysis buffer was  designed  to  inhibit  maximally 
phosphatase (23) and protease activities, as well as to disrupt intact cytoskeletal components 
(24) with which membrane proteins may be associated. Cell lysates were incubated on ice 
for 30 rain, and insoluble material was removed by centrifugation at 25,000 g for 20 min 
at 4°C.  Lysates were precleared by incubation  overnight with protein  A-Sepharose at 
4°C. After centrifugation to remove the beads, lysates were sequentially incubated for 90 
min with the control antibody UPC10-Sepharose,  followed by YZ-1, HB5,  3G8.10,  or 
W6/32-Sepharose  to immunoprecipitate CR1,  CR2,  FcR,  or HLA class  I  heavy chain, 
respectively. For the immunoprecipitation of CR3, cell lysates were first incubated for 90 CHANGELIAN  AND  FEARON  103 
rain with the nonspecific control antibody, MOPC 141 IgG, followed by addition of protein 
A-Sepharose. After centrifugation to remove the beads, CR3 was immunoprecipitated 
by sequential  incubation with  OKMI  IgG and protein  A-Sepharose.  The beads were 
washed  five  times  with  ice-cold  RIPA  buffer, and  adsorbed proteins  were eluted by 
incubation with  1% SDS for 5 rain at 100 °C. The eluates were lyophilized, redissolved in 
sample buffer without SDS, and subjected to SDS-PAGE on 5-15% polyacrylamide  slab 
gels (25). Autoradiographs were prepared by exposing dried gels to XAR X-Omat film 
(Kodak) with Cronex Xtra Life Intensifying  Screens (Dupont) at -70°C for 1-5 d. 
Results 
Analysis  of Phosphorylation  of CR1  by  Neutrophils,  Monocytes,  and  Eosino- 
phils.  To determine if stimulation of neutrophils with PMA was associated with 
the phosphorylation of CR1, s~PO4-1abeled neutrophils were prepared from two 
individuals who differed in their structural CR 1 ailotypes, having the FF and FS 
phenotypes, respectively (26, 27). Replicate samples of 5  x  10 v cells from each 
donor were incubated for 2 min at 37°C in 3 ml of buffer alone or containing 
100  ng/ml  PMA.  The  reaction  was ended  and  CR1  was immunoprecipitated 
from the cell lysates and analyzed by SDS-PAGE and autoradiography (Fig.  1). 
CR 1 was not constitutively phosphorylated in neutrophils, despite incubation for 
>90 min in the presence of 32p04. The addition of PMA led to the phosphoryla- 
tion of both the F and S allotypes of the receptor. 
The  kinetics  of PMA-induced  phosphorylation  of CR1  by neutrophils  was 
examined by incubating replicate samples of 5 x  107 cells in 3 ml of buffer alone 
or with  100 ng/ml  PMA at  37°C for 3, 6,  12, and 24 min,  respectively. After 
lysis  of the  cells,  CR1  and  the  heavy chain  of HLA class  I,  an  endogenously 
phosphorylated  protein  (28),  were  immunoprecipitated  and  analyzed  by SDS- 
PAGE and autoradiography (Fig. 2). Phosphorylation of CR1 was not detectable 
in the absence of PMA, peaked 3 rain after addition of this agent, and declined 
during the subsequent 21 rain of incubation. In contrast, the phosphorylation of 
the HLA heavy chain was constitutive and only slightly increased after addition 
of PMA to the neutrophils.  As occurred with CRI, detection of HLA phospho- 
rylation was greatly reduced by 24 min. The decline in labeling of these proteins 
observed in neutrophils may have been secondary to depletion of the intracellular 
pool of [S2P]ATP, because subsequent experiments with B lymphocytes (Fig. 6) 
demonstrated persistent labeling of HLA and complement receptors. 
The  chemotactic  peptide  FMLP  has  been  shown  to  cause  translocation  of 
intracellular  CRI to the plasma membrane (29) and to activate CR1 for phago- 
cytosis in concert with FN (8). Replicate samples of 10 s S2po4-1abeled neutrophils 
in 6 ml buffer were incubated at 37°C with  10  -7 M FMLP for 20, 60, and  180 
s, respectively. Additional samples of 5 x  107  labeled neutrophils in 3 ml buffer 
were incubated with 100 ng]ml PMA for the same intervals. The cells were lysed 
and  CR1  was  immunoprecipitated  and  analyzed.  FMLP  rapidly  induced  the 
phosphory]ation  of CRI, which peaked within  20 s of addition of the peptide, 
was  less at  60  s,  and  was almost  absent at  180  s  (Fig.  3).  In  contrast,  PMA- 
induced phosphorylation  of CR1  was undetectable at 20 s, and was greatest at 
180 s (Fig. 3). Since twice as many cells were employed for the FMLP stimulation, 
it is apparent that the maximal extent of CR1 phosphorylation induced by FMLP 
was substantially less than that caused by PMA. 104  COMPLEMENT  RECEPTOR  PHOSPHORYLATION 
FIGURE  l.  PMA-induced  phosphorylation  of  the  S  and  F  allotypes  of" neutrophil  CR1. 
Autoradiograph of SDS-PAGE analysis of CR1  from 32po4-1abeled neutrophils that had been 
treated with buffer alone (0 rain) or with  100 ng/ml PMA for 2 rain. Neutrophils were from 
individuals  who  were  heterozygous  (left)  and  homozygous  (righ 0  for  the  CR1  allotypes. 
Numbers on the right refer to the positions of standard proteins having the indicated M, X 
10  -3" 
Two other neutrophil membrane proteins  involved in  phagocytic reactions, 
CR3  and  the  FcR,  were also  analyzed for phospborylation  induced by PMA. 
Two replicate samples of 5 X 107 ~2po4-1abeled neutrophils in 3 ml buffer were 
incubated at 37°C for 3 rain in the presence or absence of 100 ng/ml PMA. The 
detergent  lysates  were  prepared  and  sequentially  immunoprecipitated  with 
UPC10,  YZ-1,  3G8.10,  and  OKM1.  The  immunoprecipitated proteins  were 
analyzed  by  SDS-PAGE  and  autoradiography.  In  the  absence  of PMA,  the 
phosphorylation of CR3 and FcR was not apparent, indicating that these mem- 
brane proteins differed from HLA class I antigen (28) in not being constitutively 
phosphorylated  (Fig.  4).  In  addition,  these  receptors  differed from  CR1  by 
exhibiting no PMA-induced phosphorylation (Fig.  4). 
The phosphorylation of CR1  by two other phagocytic cell types, monocytes 
and eosinophils, was examined. Replicate samples of 2.5  x  10 7 monocytes and CHANGELIAN AND  FEARON  105 
FIGURE 2.  Kinetics of PMA-induced phosphorylation by neutrophils of HLA class I heavy 
chain and CR 1. Membrane proteins were immunoprecipitated from 32PO4-1abeled neutrophils 
that had been treated  with buffer or with 100 ng/ml  PMA for timed intervals, and were 
analyzed by SDS-PAGE  and autoradiography. Numbers on the right refer to the positions of 
standard proteins having the indicated Mr X 10  -s. 
eosinophils that  had  been  prelabeled  with  32P0  4 were  incubated  for  3  min  at 
37°C in  3 ml buffer alone or containing 100 ng/ml PMA. CR1  and CR3 were 
immunoprecipitated  from  detergent  lysates  of the  cells  and  assessed  by  SDS- 
PAGE and autoradiography. As was found for neutrophils,  CR1  of monocytes 
was not constitutively phosphorylated but became modified in this manner upon 
stimulation of the cells with PMA for 3 min (Fig.  5  left).  CR3 of monocytes was 
not phosphorylated, constitutively or after  stimulation  (Fig.  5  left).  Analysis of 
CR1  from eosinophils that had been treated for three min with PMA indicated 106  COMPLEMENT  RECEPTOR  PHOSPHORYLATtON 
FIGURE 3.  Kinetics of neutrophil CR1  phosphorylation induced by PMA or FMLP. CR1 was 
7  $2  immunoprecipitated from 5 x  10  PO~-labeled neutrophils that had been treated with 100 
ng/ml PMA for 20, 60, or 180  s, or from 10  a ~PO4-1abeled neutrophils treated with 10 -7 M 
FMLP for the same timed intervals, and were analyzed by SDS-PAGE and autoradiography. 
The number on the right refers to the position of a standard protein having the indicated Mr 
×  10 -s. 
that the receptor on  this third phagocytic cell  type was  also capable  of being 
phosphorylated (Fig. 5 right). 
Analysis of Phosphorylation of CR1 and CR2 by B Lymphocytes.  To determine if 
phosphorylation of CR ! was restricted to phagocytic cell types, tonsilar cells were 
examined for this reaction. In addition, because these cells also express CR2, the 
C3d/EBV receptor, this membrane protein was also assessed for phosphorylation. 
Although  the  B  lymphocyte would  be  the  major  source  of CR1  in  this  cell 
population, two other potential sources are present, T  lymphocytes and macro- 
phages.  Only  10%  of T  lymphocytes express  CR1  (30),  and  the  number  of 
receptors present on these cells is <10% that present on B lymphocytes. There- 
fore, T  lymphocytes were not removed from the preparation of cells assessed for 
phosphorylation of CR1.  Conversely, macrophages express  large  amounts of 
CR 1 and three methods were used to effect their removal from the tonsilar cells. 
Each method, adherence to plastic culture dishes, adherence to Sephadex G-10, 
or elutriation, reduced the proportion of MMA  ÷ macrophages by 50% indicating 
that  it  was  not  possible  to  totally remove  this cell  type.  Therefore,  replicate 
samples  of 5  x  107  '~2PO4-1abeled tonsilar cells,  which  had  been  depleted  of 
plastic-adherent cells and which were comprised of 45% B1 + lymphocytes, 48% 
T3 + lymphocytes, and 5% MMA  + macrophages, were incubated at 37°C in 3 ml 
of buffer alone or in buffer containing 100  ng/ml PMA for 2 or 20 rain. CR1, CHANGELIAN AND  FEARON  107 
FIGURE 4.  Analysis  of CR1, FcR, and CR3 for PMA-induced phosphorylation by neutrophils. 
Membrane proteins were immunoprecipitated  from 32PO4-1abeled neutrophils that had been 
treated with buffer or with 100 ng/ml PMA for 3 rain, and were analyzed by SDS-PAGE and 
autoradiography.  Control refers to the immunoprecipitate  obtained with monoclonal UPC10 
antilevan. N  umbers on the right refer to the positions of standard proteins having the indicated 
Mr× 10  -3. 
FIGURE 5.  Analysis  of PMA-induced phosphorylation  of CR1 and CR3 in monocytes (left) 
and of CR1 in eosinophils (right).  Membrane proteins were immunoprecipitated  from 2.5 x 
107 32PO4-1abeled monocytes and eosinophils that had been treated with buffer or with 100 
ng/ml PMA for 3 rain, and were analyzed by SDS-PAGE and autoradiography.  Numbers on 
the right refer to the positions of standard proteins having the indicated Mr X 10  -3. 
CR2,  and  HLA  class  I  were  immunoprecipitated  from  each  cell  lysate,  and 
analyzed  by  SDS-PAGE  and  autoradiography.  Phosphorylation  of  CR1  was 
undetectable at to and, although detectable at 2 and 20 min following stimulation 
with PMA  (Fig.  6),  it was markedly less than that observed with the phagocytic 
cell types (Figs.  1-5).  In contrast,  CR2,  which  also was not constitutively phos- 
phorylated, became intensely labeled following B lymphocyte activation by PMA 
(Fig.  6).  Thus,  CR2,  rather  than  CR1,  is  the  predominant  phosphorylated 
complement  receptor  of the  B  lymphocyte.  Further,  CR2,  HLA,  and  CR1  all 
showed  persistent  labeling  at  20  min,  suggesting  the  intracellular  ~2p-labeled 108  COMPLEMENT  RECEPTOR  PHOSPHORYLATION 
FIGURE 6.  Analysis of PMA-induced phosphorylation of CR1, CR2, and HLA class I heavy 
chain in  tonsillar cells.  Membrane proteins were immunoprecipitated from 5  x  107  32PO  4- 
labeled tonsil cells that had been treated with buffer or with 100 ng/ml PMA for 2 or 20 rain, 
and were analyzed by SDS-PAGE and autoradiography. Numbers on the right refer to the 
positions of standard proteins having the indicated Mr X 10 -5. 
ATP pool had not been depleted in this cell population, as had probably occurred 
in neutrophils (Fig. 2). 
To characterize  further the potential  of B lymphocyte CR1  for phosphoryla- 
tion after activation of protein  kinase C, the human  B lymphoblastoid line,  SB, 
was examined. Since monocytes and neutropbils express ~50,000 CR 1 molecules 
per cell, and  SB cells express only 5,000  (P.  S.  Changelian  and  D.  T.  Fearon, 
unpublished observations), it was necessary to use  10 times as many SB cells for 
a comparable analysis.  Replicate samples of 2 ×  108 ~2PO4-1abeled  SB cells were 
incubated  in  15  ml  buffer alone  or with  100  ng/ml  PMA for 2  min  at  37°C. 
Replicate  samples  of 2  ×  107  ~2po4-1abeled monocytes in  1.5  ml  buffer  were 
identically  treated.  After  iysis,  CR1  and  CR2  from  SB  cells  and  CR1  from 
monocytes were immunoprecipitated,  and the eluted proteins analyzed by SDS- 
PAGE  and  autoradiography  (Fig.  7).  Although  phosphorylation  of monocyte 
CR1  was  readily  detectable  following  stimulation  with  PMA  for  2  min,  an 
equivalent number of CR 1 molecules from SB cells exhibited no phosphorylation. 
In  contrast,  CR2  from  SB  cells  became  intensely  phosphorylated  after  PMA CHANGELIAN AND  FEARON  109 
FIGURE 7.  Analysis of PMA-induced phosphorylation  of CR1  and  CR2  in  SB  cells and 
monocytes. Membrane proteins were immunoprecipitated  from 2 x  108 ~PO4-1abeled SB cells 
or 2 ×  107 ~2PO4-1abeled monocytes that had been  treated with buffer or with 100 ng/ml 
PMA for 2 rain, and were analyzed by SDS-PAGE and autoradiography.  Numbers  on the 
right refer to the positions of standard proteins having the indicated Mr x  10  -3. 
stimulation, analogous to the findings in normal B  lymphocytes (Fig.  6).  Buffer- 
treated SB cells displayed low levels of CR2 phosphorylation, which is in contrast 
to the  lack of constitutive  phosphorylation  of CR2  found in  tonsilar  B  lympho- 
cytes (Fig.  6).  However,  the  immunoprecipitates  from SB  cells contained  ~15- 
fold greater numbers of CR2 molecules than were present in the immunoprecip- 
itates from tonsilar cells, perhaps accounting for detection  of constitutive phos- 
phorylation. 
To determine whether  PMA  can induce phosphorylation of CR1  on another 
nonphagocytic cell type, replicate samples of 5  x  109 32PO4-1abeled erythrocytes 
were incubated at 37°C in  3  ml buffer alone or containing  100 ng/ml PMA for 
2  or  20  min.  100-fold  more  erythrocytes  were  used  because  this  cell  type 
expresses only 500  receptors/cell,  whereas myelomonocytic cells and B  lympho- 110  COMPLEMENT  RECEPTOR  PHOSPHORYLATION 
FIGURE 8.  Analysis  of  PMA-induced  phosphorylation  of CR1  in  erythrocytes.  Autoradi- 
ograph  of SDS-PAGE  analyses  of whole  cell  lysates  or  immunoprecipitates obtained  with 
UPC10  antilevan or  YZ-I  anti-CR1  from  2  ×  109  s~PO4-1abeled  erythrocytes incubated in 
buffer alone or containing  100  ng/ml  PMA for  2  or  20 min.  Arrows indicate erythrocyte 
proteins that displayed increased phosphorylation after treatment with PMA. Numbers on the 
right refer to the positions of standard proteins having the indicated Mr ×  10  -3. 
cytes express 50,000  receptors/cell. Although PMA increased the phosphoryla- 
tion of several erythrocyte proteins, phosphorylation of CR1  was not detected 
(Fig. 8). 
Discussion 
The  transition  of  CR1  on  myelomonocytic cells  from  the  resting  to  the 
activated state, in which it can mediate phagocytosis of C3b-coated particles, can 
be induced by a variety of agents. These agents, such as T  cell-derived lympho- 
kines (3),  phorbol esters (4,  5),  and extracellular matrix proteins (5,  7-9),  have 
pleiotropic effects on the cells they activate. A biochemical mechanism correlating 
this cellular activation to the activation of CR1  has not been found. In this stud), 
we have shown PMA-inducibility of CR 1 phosphorylation that is specific for cells 
of the myelomonocyte lineage, and phosphorylation of CR2 rather than of CR 1 
by B lymphocytes. 
Phosphorylation is an important mechanism for regulation of cellular protein 
function, examples being the enzymes involved in glycogen metabolism (3 l) and 
the contractile proteins of muscle cells (32). A general role for phosphorylation 
in  the activation of human neutrophils has been suggested by studies (22,  33) 
demonstrating enhanced phosphorylation of four to six proteins in cells stimu- 
lated  with  PMA or FMLP.  A  protein of Mr 44,000,  normally phosphorylated 
after PMA induction, is absent in cells from patients with chronic granulomatous 
disease (34).  These human phosphoproteins, however, have not been identified, 
in  contrast  to  studies  of rabbit  neutrophils  activated  with  FMLP,  in  which 
enhanced phosphorylation  of vimentin  (35)  and  myosin  light  chain  (36)  was 
shown. Thus, the phosphorylation of a specific protein in human neutrophils in 
association with a change in that protein's function has not been demonstrated. 
The evidence suggesting that phosphorylation of CR1  by stimulated myelo- 
monocytic cells is the structural basis for the activated state of the receptor is 
correlative. As has been found for phagocytosis by CR 1, phosphorylation of the CHANGELIAN AND  FEARON  111 
receptor did not occur constitutively in any cell type. Incubation of neutrophils, 
monocytes, and eosinophils in the presence of 32po4 for up to 90 min was not 
associated with phosphorylation of CR1, despite intense labeling of HLA class I 
heavy chain (Figs.  1-5). The absence of phosphorylation of CR 1 by unstimulated 
cells also is in contrast to the constitutive pbosphorylation of other membrane 
proteins present on these cell types, such as the transferrin receptor (37) and the 
leukocyte common antigen (T200) (38).  Therefore, the induction of phospho- 
rylation of CR 1 on myelomonocytic cells by PMA correlates with the acquisition 
of phagocytic function by CR 1. The induction of CR 1 phosphorylation by FMLP 
supports this conclusion because this chemotactic peptide also confers phagocytic 
activity on CR1  in the presence of FN (8).  The more rapid kinetics of FMLP- 
induced phosphorylation is caused by the peptide inducing a rapid turnover of 
inositol  phospholipids  (39),  with  transient  activation  of protein  kinase  C  by 
diacylglycerol. Phosphorylation of CR1  by PMA-treated monocytes and neutro- 
phils was selective, with CR3 and FcR not being subject to this form of covalent 
modification. We do not have an explanation for the absence of phosphorylation 
of CR3, which has also been reported to be functionally activated by PMA (4). 
The restriction of phosphorylation of CR1  to myelomonocytic cells is perhaps 
the most interesting finding in support  of a  causal relationship between phos- 
phorylation of CR 1 and phagocytosis. All three phagocytic cell types, neutrophils, 
monocytes, and eosinophils, were capable of phosphorylating CR1  (Figs.  1-5), 
whereas two nonphagocytic cell types, erythrocytes and normal and transformed 
B lymphocytes (Figs.  6-8), were not. This tissue-specificity of CR1  phosphoryla- 
tion may be secondary to structural differences between receptors of different 
cell types. For example, minor differences have been detected in the glycosylation 
of CR1 on different cell types that do not, however, correlate with the occurrence 
of phospborylation (40).  Differences in  the cytoplasmic domain of CR1  would 
be a  more likely mechanism accounting for the tissue-specificity of CR1  phos- 
phorylation. These differences might occur through alternative splicing of the 
CR 1 primary transcript, by analogy to the generation of membrane and secreted 
forms of immunoglobulin (41), or by the presence of multiple CR1  genes. The 
latter possibility is unlikely because CR1  ailotypes present on  myelomonocytic 
cells are  the same as  those found  on  lymphocytes and erytbrocytes (26,  42). 
Analysis of potential cell type-dependent variations in the cytoplasmic domain 
of the receptor will  now be possible  based  on  the recent cloning of a  partial 
cDNA for CR1  (43).  Two additional  mechanisms that  might account for the 
tissue-specific phosphorylation of CR1  are: different cytoplasmic environments 
regulating access of the protein kinase to CR l, and tissue-specificity of the kinase 
responsible for phosphorylation of CR1.  Although  PMA is known to activate 
protein kinase C, it cannot be concluded that protein kinase C phosphorylates 
CR1.  For  example,  other  studies  (44)  have  shown  that  phosphorylation  of 
ribosomal protein  $6  in  3T3-L1  cells treated with  PMA was  mediated by $6 
kinase rather than by protein kinase C. Whatever mecbanism is involved in CR 1 
phosphorylation, its restriction to cell types capable of engaging in phagocytosis 
suggests that this covalent modification of the receptor is related to its activation. 
Although PMA-stimulated B lymphocytes did not mediate the phosphorylation 
of CR1, CR2 was phospborylated by these cells.  This contrast may indicate that 112  COMPLEMENT RECEPTOR PHOSPHORYLATION 
CR2,  by  analogy to  CR1  of myelomonocytic cells,  has  resting and  activated 
states, the latter caused by covalent modification by phosphorylation. The recent 
reports  that simulation of B  lymphocytes with antibody to  CR2  requires  the 
presence of T  lymphocytes  or soluble factors elaborated by T cells (45-47) would 
be consistent with a  two-step process  of B  cell activation by this complement 
receptor. As CR2 also serves as the B cell receptor for EBV (12),  it will be of 
interest to determine the effects of this herpesvirus on phosphorylation of CR2. 
Summary 
CR1 of neutrophils and monocytes may exist in a resting state, in which it only 
binds ligand-coated particles, or an activated state, in which it mediates phago- 
cytosis. Because the activated state of CR 1 can be induced by the stimulation of 
protein  kinase  C  with  PMA,  CR1  was  assessed  for phosphorylation.  Purified 
human neutrophils, monocytes, eosinophils, tonsilar lymphocytes, SB cells,  and 
erythrocytes were labeled with ~2po4  and incubated with buffer or  I00 ng/ml 
PMA. Membrane proteins were immunoprecipitated and analyzed by SDS-PAGE 
and autoradiography. CR 1, unlike HLA class I heavy chain, was not constitutively 
phosphorylated by any cell type. PMA induced phosphorylation of CR1 in three 
phagocytic cell  types, but did not induce the phosphorylation of CR3  or FcR. 
FMLP also  induced the  phosphorylation of CR1  in  neutrophils.  In  contrast, 
PMA did not induce phosphorylation of CR1 in tonsilar B lymphocytes, SB cells, 
or erythrocytes, indicating restriction of this reaction to phagocytic cell types. 
This may be due to differences in the structure or presentation of  the cytoplasmic 
domain of CR1  in phagocytic vs. nonphagocytic cells.  Phosphorylation of CR2, 
however, did occur in PMA-treated B lymphocytes and SB cells, suggesting that 
this receptor, rather than CR1, may be involved in regulation of B lymphocyte 
function. 
We thank Stephanie A. Richards for assistance in monocyte purification. 
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